Chromocell Therapeutics (NYSE:CHRO) Now Covered by Alliance Global Partners

Alliance Global Partners assumed coverage on shares of Chromocell Therapeutics (NYSE:CHRO) in a report published on Tuesday morning, Marketbeat Ratings reports. The firm issued a buy rating on the stock.

Chromocell Therapeutics Stock Performance

Shares of NYSE CHRO opened at $1.37 on Tuesday. Chromocell Therapeutics has a 1-year low of $1.21 and a 1-year high of $6.00. The firm’s 50-day moving average price is $1.60.

Chromocell Therapeutics (NYSE:CHRO) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.55) earnings per share for the quarter.

Hedge Funds Weigh In On Chromocell Therapeutics

A hedge fund recently bought a new stake in Chromocell Therapeutics stock. Anson Funds Management LP purchased a new stake in shares of Chromocell Therapeutics Co. (NYSE:CHRO) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 251,888 shares of the company’s stock, valued at approximately $660,000. Anson Funds Management LP owned approximately 4.28% of Chromocell Therapeutics as of its most recent SEC filing. Institutional investors own 77.96% of the company’s stock.

About Chromocell Therapeutics

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain.